![\"Novo](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/02\/1771841950_739_w1280.jpeg\"\/)
<\/p>\nEditorial & Advertiser disclosure<\/p>\n
Global Banking & Finance Review\u00ae is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.<\/p>\n
Published by Global Banking & Finance Review\u00ae<\/p>\n
Posted on February 23, 2026<\/p>\n
1 min read<\/p>\n
Last updated: February 23, 2026<\/p>\n
<\/p>\n
COPENHAGEN, Feb 23 (Reuters) – Novo Nordisk said on Monday its next-generation obesity drug CagriSema was less effective than Eli Lilly’s tirzepatide in a head-to-head trial, a setback in the race for dominance in the weight-loss drug market.<\/p>\n
The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight, but failed to meet that goal, Novo said in a statement.<\/p>\n
The outcome is a blow to Novo Nordisk, which is fighting to regain its lost first-mover advantage in the lucrative obesity treatment market, where demand for drugs with higher efficacy is surging.<\/p>\n
Novo Nordisk’s share price fell 11% by 1002 GMT.<\/p>\n
Novo Nordisk said CagriSema achieved a 23% reduction in body weight over 84 weeks, compared to 25.5% for Eli Lilly’s tirzepatide in the trial.<\/p>\n
The results mean Novo’s next-generation treatment delivered less weight loss than Eli Lilly’s drug, which is already on the market under the brand name Zepbound and Mounjaro.<\/p>\n
Additional trials are exploring the full weight loss potential of CagriSema, including higher-dose combinations, Novo Nordisk in its statement.<\/p>\n
Lilly shares rose 4% to $1049.94 in U.S. premarket trading.<\/p>\n
(Reporting by Stine Jacobsen, editing by Terje Solsvik)<\/p>\n","protected":false},"excerpt":{"rendered":"Editorial & Advertiser disclosure Global Banking & Finance Review\u00ae is an online platform offering news, analysis, and opinion…\n","protected":false},"author":2,"featured_media":21712,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[14685,14688,272,5487,14687,14689,14686,14690],"class_list":{"0":"post-21711","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-cagrisema-vs-tirzepatide","9":"tag-eli-lilly-zepbound","10":"tag-novo-nordisk","11":"tag-novo-nordisk-stock","12":"tag-nvo-share-price","13":"tag-obesity-drug-trial","14":"tag-redefine-4-results","15":"tag-weight-loss-non-inferiority"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/21711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=21711"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/21711\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/21712"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=21711"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=21711"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=21711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}